Press coverage about Microbot Medical (NASDAQ:MBOT) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Microbot Medical earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.2000944097987 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Microbot Medical (NASDAQ MBOT) traded down $0.03 during midday trading on Friday, hitting $1.15. 485,753 shares of the stock traded hands, compared to its average volume of 832,626. Microbot Medical has a twelve month low of $1.00 and a twelve month high of $13.32.

In other news, Director Moshe Shoham sold 33,700 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $1.50, for a total value of $50,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yoseph Bornstein sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $1.18, for a total transaction of $59,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 424,310 shares of company stock valued at $520,396. Insiders own 31.83% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Microbot Medical (MBOT) Earning Somewhat Favorable News Coverage, Report Shows” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Insider Buying and Selling by Quarter for Microbot Medical (NASDAQ:MBOT)

Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with's FREE daily email newsletter.